Atsena Therapeutics, Inc.
Publicly observedDurham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Durham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Atsena Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | T7XDZVNPLRS1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1
USD 731,026.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1
USD 870,675.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.